{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T01:27:07Z","timestamp":1767835627282,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangdong Basic and Applied Basic Research Foundation-Provincial Enterprise Joint Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40256-025-00750-z","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T17:03:20Z","timestamp":1752339800000},"page":"71-82","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Retrospective Cohort Study on Long-Term Outcomes of Ticagrelor Versus Clopidogrel After Retrograde Percutaneous Coronary Intervention for Chronic Total Occlusion"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9054-9120","authenticated-orcid":false,"given":"Feihuang","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dunliang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiheng","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zehan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"key":"750_CR1","doi-asserted-by":"publisher","first-page":"198","DOI":"10.4244\/EIJ-D-18-00826","volume":"2","author":"AR Galassi","year":"2019","unstructured":"Galassi AR, Werner GS, Boukhris M, et al. Percutaneous recanalisation of chronic total occlusions: 2019 consensus document from the EuroCTO Club. EuroIntervention. 2019;2:198\u2013208.","journal-title":"EuroIntervention"},{"key":"750_CR2","first-page":"337","volume":"78","author":"DM Safley","year":"2011","unstructured":"Safley DM, Koshy S, Grantham JA, et al. Changes in myocardial ischemic burden following percutaneous coronary intervention of chronic total occlusions. Catheter Cardiovasc Interv. 2011;78:337\u201343.","journal-title":"Catheter Cardiovasc Interv"},{"key":"750_CR3","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.amjcard.2015.12.001","volume":"117","author":"X Rossello","year":"2015","unstructured":"Rossello X, Pujadas S, Serra A, et al. Assessment of inducible myocardial ischemia, quality of life, and functional status after successful percutaneous revascularization in patients with chronic total coronary occlusion. Am J Cardiol. 2015;117:720\u20136.","journal-title":"Am J Cardiol"},{"key":"750_CR4","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1093\/eurheartj\/ehy220","volume":"39","author":"GS Werner","year":"2018","unstructured":"Werner GS, Martin-Yuste V, Hildick-Smith D, et al. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J. 2018;39:2484\u201393.","journal-title":"Eur Heart J"},{"key":"750_CR5","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1161\/CIRCULATIONAHA.105.583716","volume":"16","author":"GW Stone","year":"2005","unstructured":"Stone GW, Reifart NJ, Moussa I. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. Circulation. 2005;16:2530\u20137.","journal-title":"Circulation"},{"key":"750_CR6","first-page":"511","volume":"7","author":"M Sallam","year":"2001","unstructured":"Sallam M, Spanos V, Briguori C, et al. Predictors of re-occlusion after successful recanalization of chronic total occlusion. J Invasive Cardiol. 2001;7:511\u20135.","journal-title":"J Invasive Cardiol"},{"issue":"23","key":"750_CR7","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1161\/CIRCULATIONAHA.112.097014","volume":"125","author":"S Bangalore","year":"2012","unstructured":"Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117762 patient-years of follow-up from randomized trials. Circulation. 2012;125(23):2873\u201391.","journal-title":"Circulation"},{"issue":"9711","key":"750_CR8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(09)62191-7","volume":"375","author":"CP Cannon","year":"2010","unstructured":"Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375(9711):283\u201393.","journal-title":"Lancet"},{"issue":"9749","key":"750_CR9","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","volume":"376","author":"L Wallentin","year":"2010","unstructured":"Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376(9749):1320\u20138.","journal-title":"Lancet"},{"issue":"19","key":"750_CR10","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","volume":"372","author":"MP Bonaca","year":"2015","unstructured":"Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791\u2013800.","journal-title":"N Engl J Med"},{"issue":"23","key":"750_CR11","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1001\/jama.2020.7580","volume":"323","author":"BK Kim","year":"2020","unstructured":"Kim BK, Hong SJ, Cho YH, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA. 2020;323(23):2407\u201316. https:\/\/doi.org\/10.1001\/jama.2020.7580.","journal-title":"JAMA"},{"issue":"21","key":"750_CR12","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","volume":"381","author":"R Mehran","year":"2019","unstructured":"Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381(21):2032\u201342.","journal-title":"N Engl J Med"},{"key":"750_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ahj.2018.07.013","volume":"204","author":"S Brugaletta","year":"2018","unstructured":"Brugaletta S, Gomez-Lara J, Caballero J, et al. Ticagrelor versus clopidogrel for recovery of vascular function immediately after successful chronic coronary total occlusion recanalization: a randomized clinical trial. Am Heart J. 2018;204:205\u20139.","journal-title":"Am Heart J"},{"key":"750_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.carrev.2021.06.129","volume":"37","author":"JJ Rodriguez-Arias","year":"2022","unstructured":"Rodriguez-Arias JJ, Gomez-Lara J, Caballero-Borrego J, et al. Long-term vascular function in CTO recanalization: a randomized clinical trial of ticagrelor vs. clopidogrel. Cardiovasc Revasc Med. 2022;37:61\u20137.","journal-title":"Cardiovasc Revasc Med"},{"issue":"3","key":"750_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jcin.2023.12.011","volume":"17","author":"B Lattuca","year":"2024","unstructured":"Lattuca B, Mazeau C, Cayla G, et al. Ticagrelor vs clopidogrel for complex percutaneous coronary intervention in chronic coronary syndrome. JACC Cardiovasc Interv. 2024;17(3):359\u201370. https:\/\/doi.org\/10.1016\/j.jcin.2023.12.011.","journal-title":"JACC Cardiovasc Interv"},{"issue":"5","key":"750_CR16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1161\/CIRCULATIONAHA.120.046754","volume":"143","author":"LF Ybarra","year":"2021","unstructured":"Ybarra LF, Rinfret S, Brilakis ES, et al. Definitions and clinical trial design principles for coronary artery chronic total occlusion therapies: CTO-ARC consensus recommendations. Circulation. 2021;143(5):479\u2013500.","journal-title":"Circulation"},{"issue":"1","key":"750_CR17","first-page":"64","volume":"102","author":"Y-J Zhang","year":"2023","unstructured":"Zhang Y-J, Ma W-R, Xu B, et al. Retrograde percutaneous coronary intervention of chronic total occlusion via discontinuous septal channels. Catheter Cardiovasc Interv. 2023;102(1):64\u201370.","journal-title":"Catheter Cardiovasc Interv"},{"key":"750_CR18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.119.008649","volume":"6","author":"J Mehilli","year":"2020","unstructured":"Mehilli J, Baquet M, Hochholzer W, et al. Randomized comparison of intensified and standard P2Y12-receptor-inhibition before elective percutaneous coronary intervention: the SASSICAIA trial. Circ Cardiovasc Interv. 2020;6: e008649.","journal-title":"Circ Cardiovasc Interv"},{"issue":"15","key":"750_CR19","doi-asserted-by":"publisher","first-page":"8977","DOI":"10.3390\/ijerph19158977","volume":"19","author":"A Pradhan","year":"2022","unstructured":"Pradhan A, Tiwari A, Caminiti G, et al. Ideal P2Y12 inhibitor in acute coronary syndrome: a review and current status. Int J Environ Res Public Health. 2022;19(15):8977.","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"750_CR20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/phar.2758","volume":"43","author":"CD Thomas","year":"2023","unstructured":"Thomas CD, Williams AK, Lee CR, et al. Pharmacogenetics of P2Y12 receptor inhibitors. Pharmacotherapy. 2023;43(2):158\u201375.","journal-title":"Pharmacotherapy"},{"key":"750_CR21","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/S0140-6736(20)32236-4","volume":"10264","author":"J Silvain","year":"2020","unstructured":"Silvain J, Lattuca B, Beygui F, et al. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. Lancet. 2020;10264:1737\u201344.","journal-title":"Lancet"},{"key":"750_CR22","first-page":"1244","volume":"15","author":"AN Koshy","year":"1970","unstructured":"Koshy AN, Giustino G, Sartori S, et al. Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes. EuroIntervention. 1970;15:1244\u201353.","journal-title":"EuroIntervention"},{"key":"750_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jcin.2010.09.024","volume":"2","author":"Y Morino","year":"2011","unstructured":"Morino Y, Abe M, Morimoto T, et al. Predicting successful guidewire crossing through chronic total occlusion of native coronary lesions within 30 minutes: the J-CTO (Multicenter CTO Registry in Japan) score as a difficulty grading and time assessment tool. JACC Cardiovasc Interv. 2011;2:213\u201321.","journal-title":"JACC Cardiovasc Interv"},{"key":"750_CR24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jcin.2009.10.033","volume":"4","author":"J Suh","year":"2010","unstructured":"Suh J, Park DW, Lee JY, et al. The relationship and threshold of stent length with regard to risk of stent thrombosis after drug-eluting stent implantation. JACC Cardiovasc Interv. 2010;4:383\u20139.","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"750_CR25","first-page":"346","volume":"96","author":"RF Riley","year":"2020","unstructured":"Riley RF, Henry TD, Mahmud E, et al. SCAI position statement on optimal percutaneous coronary interventional therapy for complex coronary artery disease. Catheter Cardiovasc Interv. 2020;96(2):346\u201362.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"3","key":"750_CR26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213\u201360.","journal-title":"Eur Heart J"},{"issue":"17","key":"750_CR27","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.jacc.2016.07.760","volume":"68","author":"G Giustino","year":"2016","unstructured":"Giustino G, Chieffo A, Palmerini T, et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J Am Coll Cardiol. 2016;68(17):1851\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"750_CR28","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/nrcardio.2010.116","volume":"9","author":"U Baber","year":"2010","unstructured":"Baber U, Kini AS, Sharma SK. Stenting of complex lesions: an overview. Nat Rev Cardiol. 2010;9:485\u201396.","journal-title":"Nat Rev Cardiol"},{"key":"750_CR29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.amjcard.2020.06.066","volume":"132","author":"A Sachdeva","year":"2020","unstructured":"Sachdeva A, Hung YY, Solomon MD, et al. Duration of dual antiplatelet therapy after percutaneous coronary intervention for chronic total occlusion. Am J Cardiol. 2020;132:44\u201351.","journal-title":"Am J Cardiol"},{"key":"750_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12872-019-01312-3","volume":"20","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhao HW, Wang CF, et al. Efficacy and safety ofstandard and low dose ticagrelor versus clopidogrel in east Asian patients with chronic total occlusion undergoing percutaneous coronary intervention: a single center retrospective study. BMC Cardiovasc Disord. 2020;20:1\u20138.","journal-title":"BMC Cardiovasc Disord"},{"key":"750_CR31","first-page":"e4","volume":"3","author":"JS Lawton","year":"1970","unstructured":"Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 1970;3:e4\u201317.","journal-title":"Circulation"},{"key":"750_CR32","first-page":"437","volume":"5","author":"M Valgimigli","year":"1970","unstructured":"Valgimigli M, Gragnano F, Branca M, et al. Ticagrelor or clopidogrel monotherapy vs dual antiplatelet therapy after percutaneous coronary intervention: a systematic review and patient-level meta-analysis. JAMA Cardiol. 1970;5:437\u201348.","journal-title":"JAMA Cardiol."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00750-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00750-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00750-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T14:35:38Z","timestamp":1767796538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00750-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["750"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00750-z","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,12]]},"assertion":[{"value":"29 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by scientific research funds from the National Natural Science Foundation of China (82103910) and the Guangdong Basic and Applied Basic Research Foundation-Provincial Enterprise Joint Fund (2022A1515220113).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Feihuang Han, Dunliang Ma, Song Wen, Qiheng Wan, Yuqing Huang, Feng Wang, Zehan Huang, and Bin Zhang have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Bin Zhang, Zehan Huang, Feihuang Han, designed the study. Feihuang Han, Song Wen, Qiheng Wan and Feng Wang conducted data acquisition. Zehan Huang\u00a0and Yuqing Huang performed data analysis. Feihuang Han and Dunliang Ma drafted the article. Bin Zhang performed manuscript revision. All authors read and approved the final manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The study protocol was approved by the ethics committee of Guangdong Provincial People\u2019s Hospital [No. GDREC2017196H(R1)], and all patients provided written informed consent.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for participation"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}